Next Article in Journal
Systematic Elucidation of the Mechanism of Genistein against Pulmonary Hypertension via Network Pharmacology Approach
Next Article in Special Issue
In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells
Previous Article in Journal
G Protein-Coupled Receptors (GPCRs)-Mediated Calcium Signaling in Ovarian Cancer: Focus on GPCRs activated by Neurotransmitters and Inflammation-Associated Molecules
Previous Article in Special Issue
Discontinued Drugs for the Treatment of Cardiovascular Disease from 2016 to 2018
Open AccessArticle

Isoquinolinamine FX-9 Exhibits Anti-Mitotic Activity in Human and Canine Prostate Carcinoma Cell Lines

1
Department of Medicine, Clinic III-Hematology, Oncology, Palliative Medicine, University of Rostock, 18057 Rostock, Germany
2
Small Animal Clinic, University of Veterinary Medicine Hannover, 30559 Hannover, Germany
3
Leibniz-Institute for Catalysis, University of Rostock, 18059 Rostock, Germany
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(22), 5567; https://doi.org/10.3390/ijms20225567
Received: 20 October 2019 / Revised: 4 November 2019 / Accepted: 5 November 2019 / Published: 7 November 2019
(This article belongs to the Special Issue Drug Discovery, Development and Regulatory Affairs)
Current therapies are insufficient for metastatic prostate cancer (PCa) in men and dogs. As human castrate-resistant PCa shares several characteristics with the canine disease, comparative evaluation of novel therapeutic agents is of considerable value for both species. Novel isoquinolinamine FX-9 exhibits antiproliferative activity in acute lymphoblastic leukemia cell lines but has not been tested yet on any solid neoplasia type. In this study, FX-9′s mediated effects were characterized on two human (PC-3, LNCaP) and two canine (CT1258, 0846) PCa cell lines, as well as benign solid tissue cells. FX-9 significantly inhibited cell viability and induced apoptosis with concentrations in the low micromolar range. Mediated effects were highly comparable between the PCa cell lines of both species, but less pronounced on non-malignant chondrocytes and fibroblasts. Interestingly, FX-9 exposure also leads to the formation and survival of enlarged multinucleated cells through mitotic slippage. Based on the results, FX-9 acts as an anti-mitotic agent with reduced cytotoxic activity in benign cells. The characterization of FX-9-induced effects on PCa cells provides a basis for in vivo studies with the potential of valuable transferable findings to the benefit of men and dogs. View Full-Text
Keywords: isoquinolinamine; prostate cancer; cell line; human; dog; anti-mitotic; chemotherapy isoquinolinamine; prostate cancer; cell line; human; dog; anti-mitotic; chemotherapy
Show Figures

Figure 1

MDPI and ACS Style

Schille, J.T.; Nolte, I.; Packeiser, E.-M.; Wiesner, L.; Hein, J.I.; Weiner, F.; Wu, X.-F.; Beller, M.; Junghanss, C.; Murua Escobar, H. Isoquinolinamine FX-9 Exhibits Anti-Mitotic Activity in Human and Canine Prostate Carcinoma Cell Lines. Int. J. Mol. Sci. 2019, 20, 5567. https://doi.org/10.3390/ijms20225567

AMA Style

Schille JT, Nolte I, Packeiser E-M, Wiesner L, Hein JI, Weiner F, Wu X-F, Beller M, Junghanss C, Murua Escobar H. Isoquinolinamine FX-9 Exhibits Anti-Mitotic Activity in Human and Canine Prostate Carcinoma Cell Lines. International Journal of Molecular Sciences. 2019; 20(22):5567. https://doi.org/10.3390/ijms20225567

Chicago/Turabian Style

Schille, Jan T.; Nolte, Ingo; Packeiser, Eva-Maria; Wiesner, Laura; Hein, Jens I.; Weiner, Franziska; Wu, Xiao-Feng; Beller, Matthias; Junghanss, Christian; Murua Escobar, Hugo. 2019. "Isoquinolinamine FX-9 Exhibits Anti-Mitotic Activity in Human and Canine Prostate Carcinoma Cell Lines" Int. J. Mol. Sci. 20, no. 22: 5567. https://doi.org/10.3390/ijms20225567

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop